184 related articles for article (PubMed ID: 10986219)
1. Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial.
Rees CJ; Oppong K; Al Mardini H; Hudson M; Record CO
Gut; 2000 Oct; 47(4):571-4. PubMed ID: 10986219
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.
Schmid M; Peck-Radosavljevic M; König F; Mittermaier C; Gangl A; Ferenci P
Liver Int; 2010 Apr; 30(4):574-82. PubMed ID: 20456040
[TBL] [Abstract][Full Text] [Related]
3. Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS.
Bai M; He C; Yin Z; Niu J; Wang Z; Qi X; Liu L; Yang Z; Guo W; Tie J; Bai W; Xia J; Cai H; Wang J; Wu K; Fan D; Han G
Aliment Pharmacol Ther; 2014 Jul; 40(1):63-71. PubMed ID: 24832463
[TBL] [Abstract][Full Text] [Related]
4. Hepatic encephalopathy following transjugular intrahepatic portosystemic shunt (TIPS): management with L-ornithine-L-aspartate and stent reduction.
Stadlbauer V; Tauss J; Portugaller HR; Stiegler P; Iberer F; Stauber RE
Metab Brain Dis; 2007 Mar; 22(1):45-50. PubMed ID: 17165154
[TBL] [Abstract][Full Text] [Related]
5. Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo.
Varakanahalli S; Sharma BC; Srivastava S; Sachdeva S; Dahale AS
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):951-958. PubMed ID: 29727385
[TBL] [Abstract][Full Text] [Related]
6. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations.
Nolte W; Wiltfang J; Schindler C; Münke H; Unterberg K; Zumhasch U; Figulla HR; Werner G; Hartmann H; Ramadori G
Hepatology; 1998 Nov; 28(5):1215-25. PubMed ID: 9794904
[TBL] [Abstract][Full Text] [Related]
7. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.
Stauch S; Kircheis G; Adler G; Beckh K; Ditschuneit H; Görtelmeyer R; Hendricks R; Heuser A; Karoff C; Malfertheiner P; Mayer D; Rösch W; Steffens J
J Hepatol; 1998 May; 28(5):856-64. PubMed ID: 9625322
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
[TBL] [Abstract][Full Text] [Related]
9. L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses.
Butterworth RF; McPhail MJW
Drugs; 2019 Feb; 79(Suppl 1):31-37. PubMed ID: 30706425
[TBL] [Abstract][Full Text] [Related]
10. Oral glutamine challenge in cirrhotics pre- and post-liver transplantation: a psychometric and analyzed EEG study.
Oppong KN; Al-Mardini H; Thick M; Record CO
Hepatology; 1997 Oct; 26(4):870-6. PubMed ID: 9328307
[TBL] [Abstract][Full Text] [Related]
11. Amino acid challenge in patients with cirrhosis: a model for the assessment of treatments for hepatic encephalopathy.
Douglass A; Al Mardini H; Record C
J Hepatol; 2001 May; 34(5):658-64. PubMed ID: 11434611
[TBL] [Abstract][Full Text] [Related]
12. Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study.
Jhajharia A; Singh S; Jana S; Ashdhir P; Nijhawan S
Sci Rep; 2024 May; 14(1):11862. PubMed ID: 38789596
[TBL] [Abstract][Full Text] [Related]
13. L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease.
Canbay A; Sowa JP
Drugs; 2019 Feb; 79(Suppl 1):39-44. PubMed ID: 30706422
[TBL] [Abstract][Full Text] [Related]
14. A critical analysis of studies assessing L-ornithine-L-aspartate (LOLA) in hepatic encephalopathy treatment.
Soárez PC; Oliveira AC; Padovan J; Parise ER; Ferraz MB
Arq Gastroenterol; 2009; 46(3):241-7. PubMed ID: 19918694
[TBL] [Abstract][Full Text] [Related]
15. Oral l-ornithine-l-aspartate in minimal hepatic encephalopathy: A randomized, double-blind, placebo-controlled trial.
Alvares-da-Silva MR; de Araujo A; Vicenzi JR; da Silva GV; Oliveira FB; Schacher F; Oliboni L; Magnus A; Kruel LP; Prieb R; Fernandes LN
Hepatol Res; 2014 Sep; 44(9):956-63. PubMed ID: 24033861
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy.
Abid S; Jafri W; Mumtaz K; Islam M; Abbas Z; Shah HA; Hamid S
J Coll Physicians Surg Pak; 2011 Nov; 21(11):666-71. PubMed ID: 22078345
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
Blanco Vela CI; Poo Ramírez JL
Ann Hepatol; 2011 Jun; 10 Suppl 2():S55-9. PubMed ID: 22228883
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.
Mittal VV; Sharma BC; Sharma P; Sarin SK
Eur J Gastroenterol Hepatol; 2011 Aug; 23(8):725-32. PubMed ID: 21646910
[TBL] [Abstract][Full Text] [Related]
19. Oral glutamine challenge improves the performance of psychometric tests for the diagnosis of minimal hepatic encephalopathy in patients with liver cirrhosis.
Irimia R; Stanciu C; Cojocariu C; Sfarti C; Trifan A
J Gastrointestin Liver Dis; 2013 Sep; 22(3):277-81. PubMed ID: 24078984
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study.
Poo JL; Góngora J; Sánchez-Avila F; Aguilar-Castillo S; García-Ramos G; Fernández-Zertuche M; Rodríguez-Fragoso L; Uribe M
Ann Hepatol; 2006; 5(4):281-8. PubMed ID: 17151582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
